Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition

Cognitive dysfunction is a core feature of dementia and a prominent feature in psychiatric disease. As non-redundant regulators of intracellular cAMP gradients, phosphodiesterases (PDE) mediate fundamental aspects of brain function relevant to learning, memory, and higher cognitive functions. Phosphodiesterase-4B (PDE4B) is an important phosphodiesterase in the hippocampal formation, is a major Disrupted in Schizophrenia 1 (DISC1) binding partner and is itself a risk gene for psychiatric illness. To define the effects of specific inhibition of the PDE4B subtype, we generated mice with a catalytic domain mutant form of PDE4B (Y358C) that has decreased ability to hydrolyze cAMP. Structural modeling predictions of decreased function and impaired binding with DISC1 were confirmed in cell assays. Phenotypic characterization of the PDE4BY358C mice revealed facilitated phosphorylation of CREB, decreased binding to DISC1, and upregulation of DISC1 and β-Arrestin in hippocampus and amygdala. In behavioral assays, PDE4BY358C mice displayed decreased anxiety and increased exploration, as well as cognitive enhancement across several tests of learning and memory, consistent with synaptic changes including enhanced long-term potentiation and impaired depotentiation ex vivo. PDE4BY358C mice also demonstrated enhanced neurogenesis. Contextual fear memory, though intact at 24 h, was decreased at 7 days in PDE4BY358C mice, an effect replicated pharmacologically with a non-selective PDE4 inhibitor, implicating cAMP signaling by PDE4B in a very late phase of consolidation. No effect of the PDE4BY358C mutation was observed in the prepulse inhibition and forced swim tests. Our data establish specific inhibition of PDE4B as a promising therapeutic approach for disorders of cognition and anxiety, and a putative target for pathological fear memory.


INTRODUCTION
Cognitive dysfunction is a core feature of dementia and a prominent feature in major psychiatric disorders, such as mood and chronic psychotic disorders. Consequently, there is a large unmet need for cognition-enhancing drugs. The second messenger cyclic adenosine monophosphate (cAMP) mediates fundamental aspects of brain function relevant to learning, memory, and higher cognitive functions (Richter et al, 2013). Memory formation relies on expression of genes upregulated by the transcription factor CREB (cAMP response element binding protein), which is activated when phosphorylated by PKA (protein kinase A) downstream of cAMP. As a consequence, cAMP-specific phosphodiesterase enzymes, the sole regulators of cAMP gradients and ultimately CREB, are promising targets for the development of cognition-enhancing drugs (Ghavami et al, 2006;Richter et al, 2013).
The PDE4 family is cAMP-specific and comprises four subtypes (A-D). The expression patterns of individual PDE4 subtypes are clearly distinct at the regional and cellular level, suggesting that PDE4 subtypes serve non-redundant functions. Non-subtype-selective brain-penetrant PDE4 inhibitors (targeting all of four subtypes), such as rolipram, have shown therapeutic benefit in preclinical models of psychiatric and neurological diseases (Ghavami et al, 2006;Richter et al, 2013). These models include memory and cognition impairments induced by the N-methyl-D-aspartate receptor antagonist MK-801 (Davis and Gould, 2005;Zhang et al, 2000), cerebral ischemia-induced neuron loss and associated memory deficits in rats (Li et al, 2011a), age-related memory deficits (de Lima et al, 2008), and working, reference and associative memory deficits in a transgenic mouse model of Alzheimer's disease (Gong et al, 2004).
However, non-selective PDE4 inhibitors are poorly tolerated in humans owing to nausea and emesis arising from inhibition of PDE4 in the brain stem (Mori et al, 2010) and gut (Menniti et al, 2006) at doses required for clinical effectiveness. Several lines of evidence suggest that these adverse effects are related to PDE4D, but not PDE4B (Robichaud et al, 2002). Indeed, despite comparable efficacy on other indicators, PDE4B-selective inhibitors may require doses approaching 100-fold that of PDE4D-selective agents to result in emesis, despite similar effect on other measures (Naganuma et al, 2009). Given the poor tolerability of nonselective agents, the elucidation of individual PDE4 subtype function has emerged as a strategy to guide the development of subtype-selective agents with maximal therapeutic utility and tolerability. This has, in part, been facilitated by the availability of knock-out (KO) mice deficient in individual PDE4 subtypes.
PDE4 subtypes are constitutively active enzymes containing a highly conserved catalytic domain, and then divided into categories defined by the presence of two unique, conserved domains: Upstream Conserved Region 1 (UCR1) and 2 (UCR2) (Zhang, 2009). The cAMP hydrolytic activity of PDE4B is facilitated and inhibited by PKA (Baillie, 2009) and ERK (extracellular signal-related kinase; Baillie et al, 2000), respectively. The catalytic domain and UCR1 contain phosphorylation sites for PKA and ERK, respectively. Five PDE4B isoforms have been identified in mammals: the long forms PDE4B1 (736 a.a.), 4B3 (721 a.a.) and 4B4 (659 a.a.), the short form 4B2 (564 a.a.), and the super-short form 4B5 (484 a.a.) (Cheung et al, 2007;Fatemi et al, 2008;Shepherd et al, 2003). The catalytic domain is common to all isoforms, whereas the long forms contain UCR1 and UCR2, the short form lacks UCR1, and the super-short form has only a portion of UCR2 (Zhang, 2009).
PDE4B is widely distributed throughout the brain in humans, monkeys, and rodents, with prominent expression in the cerebral cortex, limbic areas and diencephalon (Cherry and Davis, 1999;Lakics et al, 2010;Perez-Torres et al, 2000), as well as white matter tracts (Reyes-Irisarri et al, 2008). In cortex, the PDE4B1 isoform predominates, however in hippocampus and amygdala all isoforms are expressed (Reyes-Irisarri et al, 2008). Consistent with preclinical evidence of cognitive enhancement, changes in expression and subcellular localization of PDE4B in hippocampal neurons are associated with long-term potentiation (LTP) (Ahmed and Frey, 2005), considered one of the cellular mechanisms underlying learning and memory (Albensi et al, 2007). Moreover, Pde4b KO mice show an increase in the proliferation of neuronal cells in the hippocampal dentate gyrus (Zhang et al, 2008). Hippocampal slice preparations from Pde4b KO mice show markedly enhanced basal postsynaptic responses and long-term depression (Rutten et al, 2011).
Pde4b KO mice display a complex behavioral phenotype. They exhibit a moderately anxiogenic behavioral profile with decreased exploratory activity in the hole board and lightdark transition tests (Zhang et al, 2008), decreased locomotor activity in some open-field tests (Rutten et al, 2011;Siuciak et al, 2008;Zhang et al, 2008), and unaltered performance in the elevated plus maze (Siuciak et al, 2008). Pde4b KO mice perform normally in the fear conditioning (Rutten et al, 2011) and passive avoidance tests (Siuciak et al, 2008;Zhang et al, 2008), and show unaltered shock sensitivity (Rutten et al, 2011) and nociceptive responses (Siuciak et al, 2008;Zhang et al, 2008). In the Morris water maze, Pde4b KO mice show normal spatial memory acquisition and retention (Rutten et al, 2011;Siuciak et al, 2008;Zhang et al, 2008), but impaired reversal learning (Rutten et al, 2011). Acoustic startle response is increased in Pde4b KO mice, while prepulse inhibition of the startle response is decreased (Siuciak et al, 2008). They show decreased immobility in the forced swim test (Siuciak et al, 2008;Zhang et al, 2008), but not in the tail suspension test (Zhang et al, 2008). As expected, however, Pde4b KO mice show resistance to the inhibitory effects of rolipram on conditioned avoidance response (Siuciak et al, 2007). Though complex, this phenotype provides support for a role for PDE4B in both memory and anxiety.
Several lines of evidence have implicated PDE4B in major psychiatric illness, most notably schizophrenia. Disruption of PDE4B was identified by a chromosomal translocation in two first cousins with schizophrenia (Millar et al, 2005). Subsequently, large population genetic analyses of schizophrenia have inconsistently implicated single-nucleotide polymorphisms within PDE4B (Fatemi et al, 2008;Guan et al, 2012;Kahler et al, 2010;Numata et al, 2008;Pickard et al, 2007;Rastogi et al, 2009;Tomppo et al, 2009). Although an established rare genetic cause of schizophrenia, emerging primate data provide preliminary support for a role for PDE4B in the regulation of synaptic and spine plasticity in the dorsolateral prefrontal cortex and working memory (Paspalas et al, 2013). Thus, decreased PDE4B expression in post-mortem brains of patients with schizophrenia (Fatemi et al, 2008) may reflect compensatory downregulation of PDE4B to increase synaptic plasticity and counter the cognitive deficits associated with this condition, a possibility that has not received significant attention.
DISC1 is a large scaffolding protein that has important interactions with PDE4B (Millar et al, 2005;Murdoch et al, 2007). It plays key roles in neuronal development, and is a well-established risk factor for major mental illness associated with cognitive dysfunction (Blackwood et al, 2001;Porteous et al, 2014). There are five PDE4 binding sites on 100-kDa full-length DISC1; three of these sites are specific for PDE4B, while two potentially bind isoforms from each PDE4 subtype . In response to elevated cAMP levels, the shorter 71-kDa DISC1 isoform dissociates from PDE4B, whereas 100-kDa DISC1 does not dissociate, likely owing to more contact points with PDE4B .
Although poorly tolerated, non-subtype-selective PDE4 inhibitors have the potential to improve cognitive function, and several lines of evidence suggest that PDE4B may be a well-tolerated target for anxiety and cognitive enhancement. This study sought to determine the effects of specific inhibition of PDE4B by characterizing a catalytic domain mutant form of PDE4B (Y358C) that has decreased ability to hydrolyze cAMP. The catalytic domain of PDEs is an important pharmacological target, given limited homology between subtypes (Sung et al, 2003) and the well characterized relationship between existing PDE inhibitors and catalytic domains, notably clinically useful PDE5 inhibitors (Sung et al, 2003) and novel PDE4B inhibitors (Goto et al, 2013). We examined the neural and behavioral effects of the PDE4B-Y358C mutation in mice with a C57BL/6J genetic background. Our findings establish specific inhibition of PDE4B as a promising therapeutic approach for pathology affecting memory, anxiety, and fear memory.
Full methods are available in the Supplementary Methods. Sex-differences were explored with two-way analysis of variance (ANOVA), however, no significant Genotype × Sex interactions were observed. For parsimonious interpretation, statistical differences are reported using Student's t-test, linear regression, repeated measures ANOVA, and Cox regression. Post hoc tests were performed using least significant difference when significant genotype*test interactions emerged in ANOVA or repeated measures ANOVA.

RESULTS
At the cAMP binding site, there is an interaction between the central phosphate group of cAMP and H406 in WT PDE4B1 ( Figure 1a). Though the Y358 residue is located within the catalytic domain, it is neither at the site of cAMP binding nor rolipram binding (Richter et al, 2001). In the Y358C variant, a conformational change is predicted to the binding site by introducing a beta conformational bend bordering the cAMP binding cavity around K282. This severely disrupts the docking position of cAMP ( Figure 1b) as the side chain of K282 bisects the binding site.

PDE4B Y358C Alters cAMP Signaling and CREB Phosphorylation
Using VSV-epitope-tagged human PDE4B1-Y358C and WT constructs expressed in HEK-293 cells, we found that PDE4B1-Y358C has a 27% decreased ability to hydrolyze cAMP ( Figure 1c). In mouse hippocampus, RT-PCR of PDE4B1-5 did not detect expression differences between PDE4B Y358C/Y358C and PDE4B +/+ mice (Supplementary Figure 2a). Similarly, western blotting did not detect genotypic differences in expression of PDE4B1 in the hippocampus, amygdala, prefrontal cortex, and nucleus accumbens associated with Y358C ( Figure 1d; Supplementary Figure 2b and c). We probed the expression of PDE4A5, due to Y358 conservation in mouse, and PDE4D3, due to signs of upregulation in Pde4b KO mice (Zhang et al, 2008), but found no genotypic differences (Supplementary Figure 2d). Hippocampal slices from PDE4B Y358C/Y358C brains have similar levels of cAMP as PDE4B +/+ , but showed a greater cAMP accumulation when challenged with forskolin alone or in combination with rolipram (Supplementary Figure 2e). As PDE4B regulates cAMP gradients and ultimately CREB, we examined total expression of CREB and its phosphorylation (pCREB), finding increased pCREB/CREB in the hippocampi (2.5-fold) and amygdala (1.4-fold) of PDE4B Y358C/Y358C mice ( Figure 1e). The Y358C variant of PDE4B is thus normally expressed, but has reduced enzymatic activity, which in turn primes CREB signaling.

PDE4B Y358C Mice Display Decreased Anxiety and Greater Exploratory Behavior
In the elevated plus maze, mice face a conflict between aversion to open arms and motivation to explore these arms. PDE4B Y358C/Y358C mice spent more time in the open arms and made more exploratory head dips and passages than PDE4B +/+ mice (Figure 2a). In a novel open field, PDE4B Y358C/Y358C mice displayed greater ambulation and rearing activity, and spent more time in the aversive center of the arena (Figure 2b). Further, PDE4B Y358C/Y358C mice spent more time in the bright compartment of the light-dark box (Figure 2c). We exploited murine aversion to cat odors (Vyas et al, 2007) by baiting a T-maze with food pellets in one arm and bobcat urine in the opposite arm. PDE4B +/+ mice avoided the bobcat urine arm, whereas PDE4B Y358C/Y358C mice explored both arms equally (Figure 2d). This difference was not attributable to impaired olfaction (Supplementary Figure 3a).
We did not observe differences in depressive-like behavior using the forced swim test (Supplementary Figure 3b).

PDE4B Y358C Mice Display Enhanced Learning and Memory
In the Y-maze spontaneous alternation test, PDE4B Y358C/Y358C mice exhibited improvements in working spatial memory (Figure 3a). In the Morris water maze, PDE4B Y358C/Y358C mice located the escape platform faster than PDE4B +/+ mice in both acquisition and reversal training trials (Figure 3b), an effect not attributable to swimming time or speed ( Supplementary Figure 3b and c). Moreover, PDE4B Y358C/Y358C mice had improved performance compared to PDE4B +/+ mice in probe trials 24 h after the last acquisition and reversal trials (Figure 3b). In a social recognition test, PDE4B Y358C/Y358C mice demonstrated enhanced long-term (24 h) memory of a familiar juvenile compared with PDE4B +/+ mice (Figure 3c).
Object location recognition is a hippocampus-dependent task exploiting the natural exploratory activity of rodents toward spatial novelty to assess the detection of spatial relocation of a known object (Stupien et al, 2003). PDE4B Y358C/Y358C and PDE4B +/+ mice displayed similar preferences for displaced objects following a 10-min acquisition period, but only PDE4B Y358C/Y358C mice demonstrated a preference for displaced objects when the acquisition period was reduced to 5 min (Figure 3d). We have previously shown that decreasing environmental threat by dimming the lights results in increased exploration with consequent improvement in memory (Saab et al, 2009). As PDE4B Y358C/Y358C mice already display increased exploratory behavior under typical room lighting ('bright lights'; Figure 2), we sought to increase the environmental threat by exposing mice to brighter lights and a transparent arena floor at 1-m elevation. In this more aversive environment, PDE4B +/+ mice failed to show preference for displaced objects following 10 min of acquisition, but the displaced object preference of PDE4B Y358C/Y358C mice was maintained, even when acquisition was limited to 5 min (Figure 3d).

PDE4B Y358C Mice Display Altered Fear Memory
In the fear conditioning paradigm, PDE4B Y358C/Y358C mice demonstrated levels of freezing comparable with PDE4B +/+ mice in the hippocampus-dependent contextual memory test 24 h after conditioning, but showed decreased freezing in the amygdala-dependent cued memory test (Figure 3e). When a portion of this cohort was retested 7 days after conditioning, PDE4B Y358C/Y358C mice displayed less freezing to the context than PDE4B +/+ mice (Supplementary Figure 4a). Therefore, 7-day fear memory was tested in an independent cohort, in which PDE4B Y358C/Y358C mice showed lower levels of both contextual freezing and cued freezing after 7 days, in the absence of exposure at 24 h ( Figure 3f). The PDE4B Y358C/Y358C decreased freezing is not attributable to altered nociception, or to sensorimotor processing as assessed using the prepulse inhibition test ( Supplementary  Figure 4b-d).
To further examine the effect of PDE4B functional impairment on 7-day fear memory, twice daily injections of the nonselective PDE4 inhibitor rolipram (1 mg/kg) were administered to PDE4B +/+ mice from 24 h to 6 days after conditioning. Compared with vehicle-treated controls, the rolipram-treated mice exhibited a contextual memory-specific reduction in freezing (Figure 3g), supporting our PDE4B Y358C/Y358C findings.

PDE4B Y358C Mice Display Altered Synaptic Plasticity
Hippocampal CA1 electrophysiological experiments were used to explore synaptic plasticity in PDE4B Y358C/Y358C mice. The Y358C mutation did not affect basal synaptic transmission (Supplementary Figure 5). We applied forskolin, an adenylyl cyclase activator, and found increased potentiation in PDE4B Y358C/Y358C hippocampal slices, confirming decreased PDE4B-Y358C cAMP hydrolytic function (Figure 4a). To examine the effect of sustained electrical stimulation on LTP in PDE4B Y358C/Y358C mice, we utilized high frequency (100-Hz) trains and varied their number. Following tetanic stimulation with four trains, PDE4B Y358C/Y358C slices demonstrated enhanced potentiation (Figure 4b). Given the rapid acquisition observed in object recognition (Figure 3d), we employed a single 100-Hz train, which is below the typical threshold for LTP (Albensi et al, 2007). PDE4B Y358C/Y358C slices showed evidence of facilitation, whereas PDE4B +/+ slices, as expected, demonstrated non-significant potentiation (Figure 4c). We examined synaptic depression in PDE4B Y358C/Y358C mice, but observed no change in slices from 16-17-day-old mice after 900 pulses of 1-Hz stimulation ( Figure 4d). As our behavioral studies were conducted on 8-12 week old mice, we also studied an adult form of synaptic depression-depotentiation-whereby tetanic stimulation is followed by low frequency stimulation PDE4B in fear, memory, and fear memory A McGirr et al (Grunwald et al, 2001). Depotentiation restored fEPSP slopes to baseline in PDE4B +/+ slices but resulted in less synaptic depression in PDE4B Y358C/Y358C slices (Figure 4e). Pairedpulse facilitation showed no evidence that Y358C impaired presynaptic short-term plasticity (Figure 4f).

DISCUSSION
The present study sought to determine the neural and behavioral effects of a catalytic domain mutant form of PDE4B (Y358C) that has decreased ability to hydrolyze cAMP. Consistent with previous data suggesting the involvement of the Y358 residue in the interaction of PDE4B with DISC1 , our comparative molecular modeling suggested that the cysteine substitution resulted in a conformational modification rendering the DISC1 interaction site inaccessible. Confirmed in cell culture and brain tissue, the decreased binding of PDE4B-Y358C to DISC1 was associated with increased expression of DISC1 and β-arrestin1/2 in the amygdala and hippocampus, perhaps indicating compensatory mechanisms to normalize PDE4B activity. Moreover, our modeling suggested impaired cAMP binding owing to tertiary changes as a result of the Y358C substitution. Indeed, 27% impairment in cAMP hydrolytic ability of PDE4B1-Y358C observed in vitro is proportional to that of physiological regulation by phosphorylated ERK (Baillie et al, 2000). The importance of the Y358C alteration was confirmed ex vivo in forskolin-challenged hippocampal slices, which demonstrated rapid cAMP accumulation and sustained potentiation at Schaffer CA1 collaterals. PDE4B Y358C/Y358C mice consistently demonstrated low levels of anxiety in several tests, and even failed to demonstrate the natural robust innate fear response to cat odor. A decreased fear response to cat odor is also shown by mice infected with Toxoplasma gondii (Vyas et al, 2007), a schizophrenia risk factor that localizes to the lateral amygdala involved in both innate and learned fear (LeDoux, 2000). Pde4b KO mice show anxiogenic-like behaviour in the holeboard and light-dark transition tests (Zhang et al, 2008), and therefore null mutation (KO) and missense mutation (Y358C) of Pde4b appear to have opposite effects on some tests of anxiety (Rutten et al, 2011;Siuciak et al, 2008;Zhang et al, 2008). Such phenotypic differences between mice which harbor a missense mutation or null mutation (KO) of the same gene are not uncommon; for example, missense mutation I810N (Kirshenbaum et al, 2013) and KO (Ikeda et al, 2013) alleles of the Na + ,K + -ATPase α3 gene are reported to have opposite effects on the beam walking assay.
Our finding that reduced-function of PDE4B by a catalytic domain mutation results in anxiolytic effects is consistent with anxiolysis observed with non-selective PDE4 inhibitors in rodents (Li et al, 2009b;Silvestre et al, 1999) and primates (Rutter et al, 2014). Altogether these data suggest that the anxiolytic effects of non-selective PDE4 inhibitors may be PDE4B dependent.
In humans and mice, exploratory tendencies are predictive of general cognitive abilities (Matzel et al, 2006). However, an increased exploratory tendency does not equate to improvement in general cognitive performance (Light et al, 2008(Light et al, , 2011, perhaps suggesting a common substrate yet lack of causality between these factors. Reducing an environment's aversive characteristics can shift the motivation underlying exploration, resulting in learning facilitation (Saab et al, 2009). The PDE4B-Y358C mutation decreased fear responses and increased exploration in mice, and we observed a consistent pattern of cognitive enhancement in PDE4B Y358C/Y358C mice in non-aversive tests. The resistance shown by PDE4B Y358C/Y358C mice to the negative influence of environmental threat on object location memory formation suggests dissociation between fear and memory formation. Our learning and memory as well as synaptic findings are consistent with the PDE4B-Y358C mutant's reduced cAMP hydrolytic activity and facilitation of CREB phosphorylation (Tully et al, 2003).
In fear conditioning, inputs are received within the lateral amygdala to form an association between the auditory tone (conditioned stimulus) and the foot-shock (unconditioned stimulus) (LeDoux, 2000). The deficits in PDE4B Y358C/Y358C cued memory may reflect altered lateral amygdala function, consistent with β-Arrestin upregulation and the β-Arrestin-PDE4 complex required for fear conditioning (Li et al, 2009a). Yet PDE4B Y358C/Y358C mice had intact contextual (hippocampal) fear memory at 24 h, which is considered sufficient time for the formation of long-term memories (Tully et al, 2003). Pde4b KO mice, by contrast, have shown no differences in context-dependent and cue-dependent fear memory tests at 24 h (Rutten et al, 2011). The decrease in contextual freezing exhibited by PDE4B Y358C/Y358C mice when tested at 7 days is unlikely to represent extinction of fear memory, as lower contextual freezing after 7 days was observed independent of pre-exposure to the context at 24 h. Our data suggest that this is due to PDE4B dysfunction rather than disrupted interaction with DISC1 because the PDE4B Y358C/Y358C fear conditioning phenotype was replicated in control mice given subchronic rolipram, which inhibits PDE4B activity but does not affect binding to DISC1. Moreover, the replication of the phenotype when rolipram was initiated 24 h after fear conditioning suggests that PDE4B is involved in a very late process required for long-term memory persistence.
Impaired regulation of cAMP signaling in the hippocampus by PDE4B may impair a very late-phase of consolidation, perhaps by poor coordination of the late-phase protein transcription required for long-term memory persistence. Disruption of late-phase processes by injecting anisomycin or BDNF-antibodies into CA1 of the hippocampus 12 h after fear conditioning leads to a similar phenotype, with intact freezing at 48 h but decreased freezing after 7 days (Bekinschtein et al, 2007). Moreover, this phenotype has also been reported with antidepressants given 12 h after fear conditioning (Slipczuk et al, 2013). However, unlike the PDE4B Y358C/Y358C phenotype, these previous studies detected no change in fear memory at 7 days if the interventions occurred at or after 24 h (Bekinschtein et al, 2007;Slipczuk et al, 2013).
Alternatively, the degree to which the PDE4B-Y358C function facilitates the acquisition of new associations and formation of new synapses may lead to loss of behavioral specificity over time. Moreover, neurogenesis in PDE4B Y358C/Y358C mice may destabilize the fear trace (Akers et al, 2014), yet in our mice this was not linearly related to contextual fear memory. Our findings suggest that PDE4B inhibition is a putative therapeutic approach in overly persistent fear memories, typified by post-traumatic stress disorder, which would benefit from a larger prophylactic window.
In summary, the Y358C reduced-function PDE4B mutant resulted in increased phosphorylation of CREB, decreased binding of PDE4B to DISC1, and upregulation of DISC1 and β-Arrestin in the hippocampus and amygdala. PDE4B Y358C/Y358C mice displayed a phenotype of decreased anxiety, increased exploration, and cognitive enhancement across several tests of learning and memory, in parallel with hippocampal synaptic changes including enhanced LTP, impaired depotentiation, and enhanced neurogenesis. Contextual fear memory, though intact at 24 h, was decreased at 7 days and replicated pharmacologically with a non-selective PDE4 inhibitor. Our data establish specific inhibition of PDE4B as a promising therapeutic approach for disorders of memory and anxiety. Future studies should examine the neural and behavioral effects of brain-penetrant PDE4Bselective inhibitors in psychiatric and neurologic models.

FUNDING AND DISCLOSURE
This work was supported in part by grants from the Canadian Institutes of Health Research (MOP-111198; to JCR), the United Kingdom Medical Research Council (G0900625) and the National Alliance for Research on Schizophrenia and Depression (to SJC). JCR holds a Canada Research Chair in Learning and Memory. The remaining authors declare no conflict of interests.